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OBJECTIVE: Subclinical hypothyroidism is a health state that is associated with hypercholesterolemia,
infertility, iron-deficiency anemia, and poor obstetric outcome. This article summarizes the results of a
prospective clinical investigation of whether treatment of subclinical hypothyroidism and iron-deficiency
anemia with a combination of levothyroxine plus iron salt would be superior to each treatment alone.
METHODS: In a randomized, double-blind, active-controlled trial, 60 patients with subclinical hypothy-
roidism and iron-deficiency anemia received iron salt placebo (20 patients), levothyroxine placebo (20
patients), or levothyroxine iron salt (20 patients) for 3 months. Change from baseline (before) to end of
study (after) in hemoglobin, ferritin, and thyroid-stimulating hormone levels were compared among
groups.
RESULTS: The increase from baseline in hemoglobin and ferritin in the levothyroxine iron group was
superior to the other groups, in which a decrease in thyroid-stimulating hormone in the 2 groups that
received levothyroxine was superior to the group treated with iron salt.
CONCLUSION: Subclinical hypothyroidism was investigated in iron-deficient patients with no acceptable
response to iron salt alone. A combination of levothyroxine and iron salt is better than each one alone.
© 2013 Elsevier Inc. All rights reserved. • The American Journal of Medicine (2013) 126, 420-424
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aSubclinical hypothyroidism is a condition with elevated
serum thyroid-stimulating hormone in the setting of normal
total or free thyroxine (T4) concentration in serum.1 Some
atients may have vague and nonspecific symptoms of sub-
linical hypothyroidism, but most affected individuals are
symptomatic and identified during routine blood tests. The
revalence of subclinical hypothyroidism has been reported
o be approximately 4% to 10% in different geographic
opulations.1 Screening and management of subclinical hy-
othyroidism are known to be challenging and therefore of
nterest to be better understood. Subclinical hypothyroidism
as been long associated with hypercholesterolemia, athero-
clerosis, cardiovascular mortality, infertility, poor obstetric
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.1016/j.amjmed.2012.12.009utcome, neuropsychiatric symptoms, unprovoked deep
ein thrombosis, and common bile duct stones.1-5
Conditions that increase iron loss, increase demand for
iron, or decrease iron intake or absorption can produce
iron-deficiency anemia. In patients with iron-deficiency
anemia, clarifying the specific clinical conditions that cause
iron deficiency is important.
Thyroid hormones have some effects on hematopoie-
sis. Among patients with hypothyroidism, normocytic
normochromic anemia is relatively common, which is
due to a decrease in red blood cell mass and hypoprolif-
eration of erythroid progenitors.6 Thyroid hormones may
ffect hematopoiesis through an increase in erythropoie-
in production or hematopoietic factors by nonerythroid
ells.7 Anemia in hypothyroid patients in the setting of
ormal serum iron, vitamin B12, and folate could be
normalized with levothyroxine administration.8 How-
ever, hypothyroidism also has been associated with low
levels of iron, folate, and vitamin B12.7 Iron-deficiency
nemia particularly has been reported in patients with
ypothyroidism or subclinical hypothyroidism.1,2
e.
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roxine in patients with iron-deficiency anemia has beneficial
effects on iron status and blood count indices.1 However, to
the best of our knowledge, no published study has compared
levothyroxine therapy alone with levothyroxine and iron
salt combined for treating patients
with both iron-deficiency anemia
and subclinical hypothyroidism
present. The present study com-
pares the results of different treat-
ment modalities in these patients.
We hypothesized that prescription
of levothyroxine and iron salt to-
gether is superior to each one
when administered as a single
therapy.
MATERIALS AND METHODS
Study Design
Newly diagnosed individuals with
subclinical hypothyroidism were
studied at the endocrinology and
metabolism outpatient clinic at Bushehr University of Med-
ical Sciences, Bushehr, Iran. From January to November
2010, a total of 305 patients with subclinical hypothyroid-
ism (thyroid-stimulating hormone4.5-10 mU/L and nor-
mal fT4 and fT3) checked into the clinic. Of the 305 pa-
tients, 60 had newly diagnosed iron-deficiency anemia
(hemoglobin12 g/dL and ferritin25 g/L for women;
hemoglobin13.5 g/dL and ferritin30 g/L for men).
None of the patients had any indication (eg, signs and
symptoms of hypothyroidism, fatigue, constipation, depres-
sion, hyperlipidemia with total cholesterol200 mg/dL or
triglyceride250 mg/dL, positive antithyroid peroxidase
antibody120, enlarged thyroid, pregnancy, ovulatory
dysfunction, infertility, and thyroid-stimulating hor-
mone10 mU/L) requiring levothyroxine therapy.
All female patients were asked about their menstrual
period duration, frequency, and amount of bleeding. Pa-
tients with a menstrual period lasting more than 5 days or
more than usual amount of bleeding were excluded from
study. Patients with genitourinary blood loss; gastrointesti-
nal blood loss; hemolytic anemia; prior thyroid, cardiovas-
cular, respiratory, renal, and liver diseases; any chronic
diseases, including diabetes mellitus, uncontrolled hyper-
tension, adrenal insufficiency, and other endocrine disor-
ders; or any cause for anemia other than iron deficiency and
subclinical hypothyroidism were excluded from the study.
The patients were informed of the study protocol, includ-
ing the risks and benefits of the treatment modalities, and
informed consent forms were signed before participation in
the study. The study was approved by the ethics committee
of the Research Affair of Bushehr University of Medical
Sciences. All patients were evaluated by an endocrinologist
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to each one alonand a hematologist before and after therapy. Medical historyand physical examination blood sampling for complete
blood count, white blood cell differential, reticulocyte
count, fasting blood glucose, cholesterol, triglyceride, blood
urea nitrogen, creatinine, sodium, potassium, serum iron,
total iron-binding capacity, ferritin, albumin, globulin, as-
partate aminotransferase, alanine
aminotransferase, lactate dehydro-
genase, total bilirubin, and direct
bilirubin were performed. Stool
samples for occult blood and urine
analysis for hematuria were com-
pleted. Peripheral blood smears of
all patients were seen by the col-
laborating hematologist to rule out
other causes of anemia. Stool ex-
aminations for occult blood with
guaiac test, leukocytes, and para-
sites with microscopic examina-
tion were performed 3 times for
all patients. Urine dipstick exami-
nation and microscopic examina-
tion of urine after centrifugation
were performed to rule out pro-
teinuria, glucosuria, pyuria, and hematuria. Complete blood
counts were performed with the Sysmex XS-800i Fluores-
cence Flowcytometery. Serum chemistries were studied us-
ing the Slectra XL. The Berthold chemiluminescence
method was used to assay thyroid function tests, ferritin
levels, and antithyroid peroxidase antibody.
Patients with both iron-deficiency anemia and subclinical
hypothyroidism (N60) were referred to the investigator for
random assignment to ferrous sulfate (65 mg/d)matching
placebo, levothyroxine (50 g/d)matching placebo, or fer-
rous sulfate (65 mg elemental iron/d) levothyroxine (50
g/d), and they were numbered as treatment groups 1, 2, and
3, respectively. Each bottle contained medication for 90 days
of therapy. Bottles were each placed in separate but uniform
boxes, and every patient received 2 boxes according to their
randomization. Compliance was assessed by counting tablets
and asking the patients specific questions at the end of the
study. The patients were asked to contact the clinic if they
experienced any adverse events during therapy, and an assess-
ment of any complications was performed at the end of the
study.
All patients were evaluated twice (before and after ther-
apy) during the study period. Patients were instructed to
have a normal diet and advised to avoid consumption of
mineral or vitamin supplements and an excess amount of tea
and bran foods. The study primary objective was to deter-
mine changes from baseline (before) in hemoglobin to the
end of the study. Secondary end points included serum
ferritin and thyroid-stimulating hormone change from base-
line to the end of study. All patients were able to contact the
clinic by telephone during the study period as needed. Of
note, 100% of the patients (N60) completed the study per
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No formal power analysis was conducted to estimate the
sample size in the study. After randomizing 61 patients into
the study at a 1:1:1 ratio stratified by gender, enrollment
stopped because of the unavailability of additional patients
meeting inclusion and exclusion criteria. One patient was
later lost to follow-up, and 60 patients equally randomized
between groups and gender within each group were used to
evaluate the objectives of the study. Normally distributed
data are reported as mean standard deviation, and count
data are reported by N (%). Paired t test was used to
compare before and after measurements in each treatment
group for each of the primary and secondary end points.
Analysis of variance model was used to compare changes
from baseline in hemoglobin, serum ferritin, and thyroid-
stimulating hormone across treatment groups and baseline
characteristics (age, gender, and weight). A P value .05
as considered statistically significant. Data processing and
tatistical analysis were performed by using SPSS 15.1
SPSS Inc, Chicago, Ill).
RESULTS
No treatment-related adverse events were reported in any of
the treatment groups. All patients were asymptomatic and had
Table 1 Baseline Characteristics and After Treatment
Parameters
Parameters
Treatment Groups*
Iron Placebo
Levothyroxine
Placebo
Iron
Levothyroxine
N 20 20 20
Gender (n %)
Male 10 (50%) 10 (50%) 10 (50%)
Female 10 (50%) 10 (50%) 10 (50%)
Age (y) 32.8 6.83 33.6 6.80 33.8 6.79
Weight (kg) 74.4 9.42 74.0 10.93 73.5 10.5
*Age and weight are reported as mean standard deviation. There
were no statistical differences between groups.
Table 2 Baseline Characteristics and After Treatment Paramete
Parameters
Treatment Groups*
Iron Placebo Levothyroxine
Before After P Value† Before
Hb (g/dL) 11.67 0.983 11.67 1.07 .956 12 0.946
erritin (ng/mL) 16.75 6.06 17.55 5.26 .572 17.25 5.68
SH (IU/mL) 8.12 1.22 7.54 1.81 .136 8.36 0.917
Hb hemoglobin; TSH thyroid-stimulating hormone.
*Summaries are reported as mean standard deviation.
†P values from paired t test.
‡P values compare “before” values between groups.no goiter and positive thyroid peroxidase antibody. The ob-
served range of menstrual period for female patients included
in the study was 2 to 5 days and not different between groups.
Baseline characteristics and laboratory data for all treat-
ment groups are shown in Tables 1 and 2. There were no
statistical differences found at baseline between the groups
with regard to gender, age, weight (Table 1), hemoglobin,
thyroid-stimulating hormone, and ferritin (Table 2). There
were no statistically significant differences in the menstrual
blood loss between the treatment groups before and during
the study. All stool examination results for occult blood
were negative. Within each treatment group, before and
after measurements were compared. There were no signif-
icant differences in hemoglobin, ferritin, and thyroid-stim-
ulating hormone in the ironplacebo treatment group.
There were no significant differences in hemoglobin or
ferritin in the levothyroxineplacebo treatment group, but
thyroid-stimulating hormone decreased significantly
(P .001). There were significant increases in hemoglobin
and ferritin and significant decreases in thyroid-stimulating
hormone in the iron levothyroxine treatment group
(P .001) (Table 2). Hemoglobin and ferritin normalized
(hemoglobin12 g/dL and ferritin10 ng/mL for women;
emoglobin13.5 g/dL and ferritin29 ng/mL for men)
or most subjects treated with iron levothyroxine therapy
but not with the other 2 treatments. Thyroid-stimulating
hormone normalized (thyroid-stimulating hormone4.5
IU/mL) for all patients in the levothyroxineplacebo and
iron levothyroxine treatment groups but not in the
ironplacebo treatment group.
An increase in hemoglobin was most pronounced in
the iron levothyroxine treatment group (1.17 g/dl)
compared with the levothyroxine placebo group (0.26
g/dL) and iron placebo group (0.005 g/dL) (Table 3).
This increase in hemoglobin was highly significant
(P .0001) when the iron levothyroxine treatment
group was compared with either of the other treatment
groups. A similar statistical benefit in ferritin increase
was observed across treatment groups (P .0001), with a
clear advantage for the iron levothyroxine group with
an average 10.78 ng/mL increase in the values compa-
Baseline
ComparisonIron Levothyroxine
P Value† Before After P Value† P Value‡
0.957 .101 11.7 0.988 12.88 0.831 .001 .504
6.37 .501 17.1 5.54 27.72 5.58 .001 .961
1.32 .001 8.04 1.43 2.9 1.71 .001 .683rs
Placebo
After
12.26
17.77
2.61
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423Ravanbod et al Hypothyroidism, Iron-deficiency Anemiared with 0.611 and 0.722 ng/mL increases in the
levothyroxine placebo and iron placebo groups,
respectively.
An increase in hemoglobin and ferritin in each group had
no significant differences between men and women. An
increase in hemoglobin and ferritin in female patients was
less than in male patients but without statistical significance.
Female patients did not report a change in menstrual period
(duration, amount, and frequency of bleeding) during the
study period. No significant differences between men and
women in each group were detected in thyroid-stimulating
hormone.
Both the iron levothyroxine and levothyroxineplacebo
groups demonstrated superiority (P .0001) over the
ronplacebo group with regard to a decrease in thyroid-
timulating hormone, 5.12 and 5.75 mIU/L, respectively, over
.58 mIU/L in the ironplacebo group.
DISCUSSION
It is common and acceptable to treat patients of all ages with
subclinical hypothyroidism with levothyroxine when thy-
roid-stimulating hormone is10 mU/L9,10 and nonelderly
atients when thyroid-stimulating hormone is4.5 mU/L
hen one of the following is present: symptoms suggestive
f hypothyroidism, presence of high titers of antithyroid
eroxidase antibodies, thyroid enlargement,11 or pregnancy.
atients with iron-deficiency anemia should be treated with
ron-replacement therapy and evaluated to determine the
ause of iron deficiency. Furthermore, subclinical hypothy-
oidism has a known association with iron-deficiency ane-
ia,1,2 and all patients with iron-deficiency anemia who
have no definite cause of blood loss or iron malabsorption
may need to be examined for subclinical hypothyroidism.
Both diseases may need to be treated if no acceptable
response to iron salts is achieved. The causes of iron-
deficiency anemia basically are low iron intake, iron mal-
absorption, and blood loss. Subclinical hypothyroidism may
cause iron malabsorption or a decrease in iron incorpora-
tion, and as a result an increase in iron loss.
The study results demonstrated that treatment of patients
with subclinical hypothyroidism and iron-deficiency anemia
with a combination of iron levothyroxine resulted in a
favorable outcome compared with treatment of patients with
Table 3 Comparison of Before and After Treatment Differences
Change From Baseline
(After, Before)
Treatment Groups*
Group 1:
Iron Placebo
Group 2:
Levothyroxine Placebo
Group
Iron
Hb, g/dL 0.005 0.39 0.26 0.675 1.17
Ferritin, ng/mL 0.722 5.32 0.61 3.77 10.78
TSH, mIU/L 0.580 1.67 5.75 1.41 5.12
Hb hemoglobin; NS not significant; TSH thyroid-stimulating ho
*Summaries are reported as mean standard deviation.monotherapy of iron or levothyroxine alone. Hemoglobin as athe leading indicator for improvement in anemia and thy-
roid-stimulating hormone as an indicator for subclinical
hypothyroidism both improved significantly (P .0001) in
patients treated with the combination therapy compared
with monotherapy (Table 3). Our study showed that iron or
levothyroxine replacement alone in the patients with iron-
deficiency anemia and subclinical hypothyroidism did not
improve hemoglobin and ferritin levels, and that the best
results were achieved with the combined prescription of
iron levothyroxine. No increase in ferritin level was ob-
served in patients treated with iron or levothyroxine alone,
indicating that correcting thyroid function is necessary to
improve iron status in patients with subclinical hypothyroid-
ism and iron-deficiency anemia, most likely because of
improved absorption of iron or prevention of iron loss.
These findings mean that the patients with iron-defi-
ciency anemia who have no acceptable response to iron
replacement should be studied for possible causes, in-
cluding subclinical hypothyroidism, and if the 2 condi-
tions coexist, levothyroxine therapy should be added to
iron salt. Furthermore, iron salt alone had no significant
effects on thyroid-stimulating hormone level when com-
pared with the other 2 groups treated with levothyroxine
or iron levothyroxine. Prescription of iron salt in the
patients with iron-deficiency anemia and subclinical hy-
pothyroidism had no significant effect on thyroid-stimu-
lating hormone level, which differs from the results ob-
tained by Gokdeniz et al,12 who showed that iron
eplacement in patients with iron-deficiency anemia and
ormal thyroid function significantly decreases thyroid-
timulating hormone level and increases free T4 level.
oreover, some studies showed that iron deficiency with
r without anemia has adverse effects on thyroid physi-
logy.13,14 Iron-deficiency anemia can affect thyroid me-
tabolism through several mechanisms, such as decreased
oxygen transport of anemia (similar to hypoxia), influ-
ence of iron deficiency on iodine deficiency disorders
through alteration of central nervous system control of
thyroid metabolism, and modification of nuclear T3 bind-
ing and altered thyroid peroxidase activity.15 Iron sup-
lementation also has some beneficial effects on goiter in
odine-deficient patients with iron deficiency.16,17 We did
ot observe a significant effect of iron-replacement ther-
en Groups
P Value
yroxine Group 1 vs Group 2 Group 1 vs Group 3 Group 2 vs Group 3
NS .0001 .0001
NS .0001 .0001
.0001 .0001 NSBetwe
3:
Levoth
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424 The American Journal of Medicine, Vol 126, No 5, May 2013due to concomitant iodine deficiency or an insufficient
power of the iron effect on thyroid-stimulating hormone
in the setting of hypothyroidism or levothyroxine pre-
scription. As a result, considering iron replacement ther-
apy to correct abnormal thyroid function, especially in
the absence of iron-deficiency anemia, does not seem to
be reasonable, and further studies are needed to clarify
this finding better.
Hypothyroidism is associated with iron-deficiency ane-
mia, pernicious anemia, celiac disease, small intestine bac-
terial overgrowth, gastric atrophy, and decreased gut motil-
ity.1,18,19 Hypothyroid patients with iron-deficiency anemia
espond adequately to levothyroxine and iron salt. Further-
ore, hypothyroidism may have some effects on iron ab-
orption by a decrease in acid secretion. Gastric acid de-
rades the organic iron complex (vegetable protein),
educes the trivalent mineral to ferrous iron, and improves
roximal small-bowel absorption of iron. As a result, levo-
hyroxine prescription can reverse the deleterious effects of
hyroid hormone deficiency on iron absorption.1,18,19
Hypothyroid women in their childbearing years may de-
velop iron deficiency secondary to menorrhagia, and levothy-
roxine can improve the hemoglobin level by affecting men-
strual blood loss. In our study, female patients did not report a
change in their menstrual period or the amount of bleeding
during the study period. Furthermore, male and female patients
showed an approximately equal amount of hemoglobin and
ferritin increment in each group. As a result, levothyroxine use
in patients with subclinical hypothyroidism had no significant
effect on menstrual bleeding in our study, but we should keep
in mind that there were too many subjects in each group to
stratify sex; thus, the statistical analysis had insufficient power
to reveal any gender effect.
CONCLUSIONS
To the best of our knowledge, our study is the first study to
compare iron salt, levothyroxine, and iron salt levothyroxine
in the treatment of subclinical hypothyroidism and iron-defi-
ciency anemia. Our results indicated that levothyroxine iron
alt was superior to other treatment modalities. It is important
o consider subclinical hypothyroidism when iron salt is not
ffective in iron-deficiency anemia, especially in endemic ar-
as of iodine deficiency and goiter. Therefore, we suggest
rescription of levothyroxine iron salt in patients with coex-
stent subclinical hypothyroidism and iron-deficiency anemia.
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